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Abstract
The number of new chemicals that are being synthesized each year has been steadily increasing. 
While chemicals are of immense benefit to mankind, many of them have a significant negative 
impact, primarily owing to their inherent chemistry and toxicity, on the environment as well as 
human health. In addition to chemical exposures, human exposures to numerous non-chemical 
toxic agents take place in the environment and workplace. Given that human exposure to toxic 
agents is often unavoidable and many of these agents are found to have detrimental human health 
effects, it is important to develop strategies to prevent the adverse health effects associated with 
toxic exposures. Early detection of adverse health effects as well as a clear understanding of the 
mechanisms, especially at the molecular level, underlying these effects are key elements in 
preventing the adverse health effects associated with human exposure to toxic agents. Recent 
developments in genomics, especially transcriptomics, have prompted investigations into this 
important area of toxicology. Previous studies conducted in our laboratory and elsewhere have 
demonstrated the potential application of blood gene expression profiling as a sensitive, 
mechanistically relevant and practical surrogate approach for the early detection of adverse health 
effects associated with exposure to toxic agents. The advantages of blood gene expression 
profiling as a surrogate approach to detect early target organ toxicity and the molecular 
mechanisms underlying the toxicity are illustrated and discussed using recent studies on 
hepatotoxicity and pulmonary toxicity. Furthermore, the important challenges this emerging field 
in toxicology faces are presented in this review article.
Keywords
blood; transcriptomics; liver; hepatotoxicity; lungs; pulmonary toxicity
*Correspondence to: Pius Joseph, MS 3014, National Institute for Occupational Safety and Health (NIOSH), 1095 Willowdale Road, 
Morgantown, WV 26505. pcj5@cdc.gov. 
Disclaimer
The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the National 
Institute for Occupational Safety and Health.
HHS Public Access
Author manuscript
J Appl Toxicol. Author manuscript; available in PMC 2015 August 26.
Published in final edited form as:














Human exposure to toxic agents and the potential adverse effects these agents have on 
human health are of major concern among healthcare providers, industrial hygienists, and 
regulatory and public health agencies. While the vast majority of toxic agents commonly 
encountered in the environment and work-places are chemicals, exposure to toxic agents of 
a non-chemical origin also contributes significantly to the morbidity and mortality of 
exposed individuals. Toxic agents, either from the environment or the workplace, fall under 
various categories including, but not limited to, metals, organic solvents, pesticides, 
aromatic hydrocarbons, acids, bases and naturally occurring substances, etc. (Thorne, 2007). 
Even the pharmaceutical industry, whose main objective is to develop, manufacture and sell 
potentially life-saving drugs, is a source of occupational exposure to toxic agents to tens of 
thousands of workers.
The potential adverse health effects resulting from human exposure to toxic agents can range 
from minor discomfort to life-threatening diseases. Ever since the report by Sir Percival Pott 
in 1775 documenting an association between occupational exposure to soot particles and the 
incidence of scrotal cancer among chimney sweeps, there have been numerous reports 
confirming the role played by toxic agents originating in the environment and occupational 
settings in the diseases and death reported among human beings. Virtually every organ and 
organ system in the human body, namely skin, nervous system, eye, respiratory system, 
cardiovascular system, liver, kidney, reproductive system, endocrine system, etc. have been 
identified as a target for toxicity and diseases resulting from exposure to various toxic agents 
(Thorne, 2007).
Prevention of morbidity and mortality associated with diseases arising from exposure to 
toxic agents is an important goal of toxicology research. It has been well recognized that the 
key elements in the prevention of diseases associated with exposure to toxic agents are a 
clear understanding of the mechanisms, especially those at the molecular level, responsible 
for the onset and progression of toxicity as well as the ability to detect the earliest response/
effect in the exposed individual. The early pre-clinical effects that occur well before the 
onset of any clinical symptoms are mostly reversible and, therefore, provide the most 
appropriate window of opportunity to apply effective intervention strategies based on 
toxicity mechanisms to prevent the onset of irreversible toxicity and diseases resulting in 
morbidity and mortality.
The potential risk for exposure to toxic agents and the resulting toxicity can be determined 
by monitoring for the presence of toxic agents either in the environment or the workplace 
(external dose) or in the target organs/tissues (internal dose) of the exposed population 
(Simmons et al., 2005; Van de Sandt et al., 2007). Several biomarkers indicative of the 
interaction between a toxic agent and its respective target organ have been developed to 
determine the toxicity resulting from exposure to the toxic agent (Lacour et al., 2005; 
Rockett & Kim, 2005; Thukral et al., 2005; Wallace et al., 2004). Adducts of chemicals 
and/or their metabolites with cellular macromolecules such as DNA (Matter et al., 2007; 
Gyorffy et al., 2008) and protein (Hagmar et al., 2001; Heubi, 2007) have been used as 
indicators of exposures to toxic agents and the potential toxicity of such exposures. 
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Assaying enzyme activity and quantitation of biochemical constituents in target organs/
tissues and biofluids such as blood and urine have also been employed as markers of toxicity 
(Benyounes et al., 2006; Iseri et al., 2007; Patlolla & Tchounwou, 2005).
Most of the currently available biomarkers are of limited use as effective toxicity markers 
owing to various limitations. These include, but are not limited to, the lack of specificity 
and/or lack of sensitivity to predict toxicity well before the onset of clinical symptoms. In 
addition, most of the currently available toxicity biomarkers do not provide significant 
information regarding the mechanisms underlying the toxicity. Therefore, there is a need to 
develop better biomarkers for toxicity that are more sensitive, specific and mechanistically 
relevant. Ideally, these biomarkers should be measurable, in easily accessible tissues or 
biofluids which can serve as surrogates for the inaccessible target organs/tissues. The ease 
and accessibility of using surrogate tissues will facilitate human monitoring of exposure to 
toxic agents such as those taking place from environmental and occupational sources.
Toxicogenomics, a relatively new branch of toxicology, employs the recent developments in 
genomics, especially transcriptomics, to study toxicity. Toxicogenomics has the potential to 
advance the understanding of how multiple genes are involved in cellular responses upon 
exposure to toxic agents (Afshari et al., 1999; Nuwaysir et al., 1999; Pennie et al., 2000; 
Olden, 2004). A primary tenet of toxicogenomics is that the effects of toxic agents on 
cellular functions are mediated through gene expression changes, both as primary and 
secondary effects. Biological processes are regulated by expression level changes of large 
numbers of genes organized as specific biological functions, pathways and networks. Toxic 
agents, upon entering the body, may cause alterations in the expression of one or several 
genes to result in the functional disruption of the corresponding biological functions, 
networks and pathways that are vital for normal functioning of the cells/tissues/organs. 
Therefore, alterations in the expression levels of genes that are involved in specific 
biological functions, pathways and networks regulating vital functions in the body may be 
reflective of the toxicity. There is substantial evidence suggesting that gene expression 
changes in target organs indicative of toxicity appear earlier than the onset of classic toxicity 
indicators such as biochemical and histological changes (Heinloth et al., 2004). Therefore, 
determination of gene expression changes in target organs in response to exposure to toxic 
agents may provide a window of opportunity for the preclinical diagnosis of toxic end points 
and the application of effective intervention strategies to prevent the resulting adverse health 
effects.
Gene expression profiling in target organs has been successfully employed to detect, classify 
and predict toxicity (Buck et al., 2008; Heinloth et al., 2004; Irwin et al., 2004; Konig et al., 
2008; Mendrick, 2008). Furthermore, gene expression profiling can provide significant 
insight regarding the mechanism(s) underlying target organ toxicity (Amin et al., 2004; 
Beyer et al., 2007; Waring et al., 2001a). In one study, Steiner et al. (2004) determined the 
gene expression profiles for rats treated with one of 18 chemicals including several well-
characterized hepatotoxicants. The aim of their study was to determine whether biological 
samples from rats treated with a toxic compound could be classified based on their gene 
expression profiles. The authors were able to differentiate the rats exposed to the 
hepatotoxic chemicals from those exposed to the non-hepatotoxic chemicals based on liver 
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gene expression profiles. The potential application of gene expression profiling in target 
organs to classify chemicals based on their toxicity has also been demonstrated by the 
results obtained from many other investigations (Burczynski et al., 2000; Hamadeh et al., 
2002a, 2002b; Thomas et al., 2001).
Gene expression profiling may also provide valuable mechanistic data which can be used in 
the risk assessment of all chemicals as well as to design and apply effective intervention 
strategies to prevent toxicity and associated adverse health effects. Waring et al. (2001a, 
2001b) treated primary rat hepatocytes with one of 15 independent hepatotoxic chemicals, 
and the resulting gene expression profiles were determined employing microarrays. The 
various hepatotoxic chemicals used in the study differed with respect to the underlying 
mechanisms causing hepatotoxicity such as DNA damage, oxidative stress and induction of 
cytochrome P450 enzymes. Hierarchical clustering of the hepatotoxicity responsive genes in 
the treated cells demonstrated distinct gene expression signatures suggesting that the 
compounds could be classified into various groups based on the underlying mechanism(s) of 
hepatotoxicity. In another previous study, Hamadeh et al. (2002b) employed gene 
expression profiling to distinguish chemicals between two types of hepatotoxins based upon 
their mechanisms of toxicity in rats in vivo. The authors were able to distinguish the toxicity 
of peroxisome proliferators (clofibrate, Wyeth 14,643 and gemfibrozil) from that of an 
enzyme inducer (phenobarbital) based on distinct gene expression profiles from the livers of 
the rats.
A major drawback of the toxicogenomics data reported so far is that most, if not all, were 
derived from studies which used either cell culture (Waring et al., 2001a, 2001b) or 
laboratory animals (Amin et al., 2004; Hamadeh et al., 2002b, 2002c) as experimental 
models. Employing gene expression profiling to monitor toxicant exposure and/or effect in 
an inaccessible organ/tissue in humans is a difficult prospect. In most cases, direct biopsy of 
organs/tissues is not feasible.
Where humans are concerned, the use of gene expression profiling to determine toxicant 
exposures or predict possible toxicity outcomes is largely limited to the use of accessible 
biospecimens. One possible solution is to use easily accessible tissues that reflect similar 
gene expression changes as a given target organ. These surrogate tissues could offer a non-
invasive or minimally invasive and convenient biomonitoring method to provide insight into 
the effects of toxicants on target organs (Rocket, 2006). The major biospecimens currently 
being used as surrogate tissues include placenta, hair, nail, milk, urine, blood, breath 
condensate, buccal cells, saliva, nasal lavage and bronchial lavage (Rockett & Burczynski, 
2006).
Blood has several advantages over other surrogate tissues and is often considered the 
preferred surrogate tissue for inaccessible target organs in the body. The major benefits of 
using blood as the surrogate tissue for gene expression profiling studies, especially in 
human, are:
1. Blood is available from almost everyone and is collected routinely for diagnostic 
purposes.
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2. Small quantities of blood can yield adequate quantities of high-quality RNA 
required for gene expression profiling.
Several previous studies conducted in the past have demonstrated the use of blood as the 
preferred surrogate tissue for gene expression profiling to identify markers of functional 
impairment in inaccessible organs in the body. Blood gene expression profiling has also 
been successfully employed as a diagnostic indicator of abnormal organ function under 
various disease conditions. For example, Burczynski et al. (2005) identified a specific set of 
predictor genes, capable of distinguishing between the peripheral blood mononuclear cells 
(PBMCs) of renal cell carcinoma patients and normal volunteers with high accuracy. 
Similarly, peripheral blood has been successfully employed as a surrogate tissue for gene 
expression studies to identify disease conditions such as ischemic stroke (Moore et al., 
2005), neurologic diseases (Tang et al., 2005), Huntington’s disease (Borovecki et al., 
2005), lupus (Baechler et al., 2003) and migraine (Hershey et al., 2004).
There have been a limited number of studies conducted in the past demonstrating the use of 
gene expression studies using blood as a surrogate tissue to determine chemical exposure 
and the resulting toxicity. Ember et al. (2000) and Gyongyi et al. (2001) administered 1-
nitropyrene and 7,12-dimethylbenz(a) anthrazene, respectively, in rats and determined gene 
expression profiles in the PBMCs and several internal target organs (lung, liver, lymph 
nodes, kidneys and spleen). Results of these studies demonstrated that the expression levels 
of two oncogenes (H-ras and c-myc) and a tumor suppressor (p53) responded to 
administration of the chemicals, with a good correlation in gene expression between the 
PBMCs and the target organs. Thus the expression levels of these genes in the PBMCs 
might be early biomarkers of exposure to the tested chemicals, and PBMCs may be used as 
an effective surrogate for certain internal target organs. Recently, McHale et al. (2007) 
employed gene expression profiling in PBMCs as a measure for exposure to 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) in a population in Seveso, Italy. Higher blood levels of 
TCDD in the exposed individuals correlated with the expression of specific genes in 
PBMCs, suggesting that blood gene expression profiling can be used to identify biomarkers 
for toxicant exposure in humans. Furthermore, the appearance of chloracne in individuals 
who were accidentally exposed to TCDD was associated with a distinct blood gene 
expression profile compared with unexposed individuals. Results of an exploratory study 
conducted by Wang et al. (2005) determined global gene expression profiles in whole blood 
samples of workers occupationally exposed to metal fume. Several genes involved in 
biological processes related to inflammatory response, oxidative stress, intracellular signal 
transduction, cell cycle and programmed cell death were differentially expressed in workers 
exposed to metal fume compared with non-exposed controls.
Recent studies conducted in our laboratory as well as those by investigators in other 
laboratories have strengthened the argument that blood gene expression profiling might be a 
valuable surrogate approach not only to detect early target organ toxicity but also to obtain 
insight into the molecular mechanisms underlying the target organ toxicity. The remainder 
of this article is dedicated to discuss the findings obtained from studies in which blood gene 
expression profiling has been employed as a surrogate approach to detect and study 
hepatotoxicity and pulmonary toxicity. Efforts are made not only to demonstrate the 
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advantages of employing blood gene expression profiling in detecting and studying target 
organ toxicity but also to address the challenges this emerging field in toxicology faces.
Blood gene expression profiling and hepatotoxicity
The liver is the primary target organ for a vast majority of toxic agents owing to its central 
role in chemical metabolism. This is best illustrated in the case of drug-induced liver injury 
(DILI). DILI is the major reason for both the failure of regulatory approval of new drug 
candidates and withdrawal or limitation of use of already approved and marketed drugs. 
Primarily as a result of the inability to obtain human liver samples to determine DILI, there 
has been immense pressure to develop alternative, sensitive, specific, reliable, 
mechanistically relevant and non-invasive or minimally invasive biomarkers for DILI. Even 
though serum levels of transaminases have been routinely employed as surrogate clinical 
markers of DILI, concerns have been raised especially with respect to their lack of 
sensitivity. Structural and/or functional impairment of the liver is a prerequisite for 
observable alterations in the levels of serum transaminases. In addition, elevated serum 
transaminase levels do not provide any mechanistic insight into DILI. In view of these 
limitations, investigations have been carried out in recent years to determine the suitability 
of peripheral blood gene expression profiling as a sensitive, specific and mechanistically 
relevant surrogate approach to detect and study liver toxicity induced by drugs and other 
toxic agents.
One of the pioneer studies in this field was carried out by investigators at the National 
Institute for Environmental Health Sciences (NIEHS) employing acetaminophen (APAP), a 
drug that has been implicated in numerous cases of human DILI (Bushel et al., 2007). Rats 
were given toxic or sub-toxic oral doses of APAP; and the resulting hepatotoxicity, or the 
lack thereof, was determined on the basis of established toxicity markers including serum 
transaminases, hematological parameters and liver histology. Total RNA was isolated from 
blood samples obtained from the control and APAP administered rats and global gene 
expression profiles were determined by microarray analysis to develop blood gene 
expression signatures capable of predicting APAP exposure and APAP-induced 
hepatotoxicity. Findings of the study suggested that changes in the whole blood 
transcriptome, indicative of APAP-induced hepatotoxicity, preceded changes in the 
traditional hepatotoxicity markers employed in the study. Furthermore, the blood gene 
expression signatures were able to accurately predict the rats which were given the sub-toxic 
oral dose of APAP. Subsequently, Zhang et al. (2012) applied the method Extracting 
Patterns and Identifying co-expressed Genes (EPIG) to the transcriptomics data obtained 
from the Bushel et al. (2007) study to investigate to what extent changes in blood 
transcriptome mirror those in the livers of the APAP-administered rats. Similar expression 
changes were found to be occurring in a sub-set of genes in the blood and liver of the 
APAP-administered rats. Some of the parallel transcript changes in the blood and liver 
reflected pathways that are relevant to APAP-induced hepatotoxicity including 
mitochondrial oxidative phosphorylation and immune function. Although the number of 
genes that demonstrated coordinate regulation between the liver and blood represented only 
a small fraction of the total affected genes, the similarities in the pathways and functions 
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linked to these genes support the idea that transcriptomics analysis of blood can provide 
mechanistic insight into DILI.
A notable finding of the study by Bushel et al. (2007) was the superior sensitivity of blood 
gene expression markers as predictors of hepatotoxicity compared with the traditional 
toxicity markers in the rats. This was further confirmed by Lobenhofer et al. (2008) who, 
using a compendium of eight non-therapeutic hepatotoxic chemicals, investigated whether it 
was possible to classify histopathological differences, most likely reflecting differences in 
mechanisms of cell-specific toxicity, using either liver (target organ) or blood (surrogate 
tissue) transcriptomics. The results of this study demonstrated that it was possible to classify 
the hepatotoxicants based on the gene expression profiling data derived from either liver or 
blood. In fact, the blood gene expression data performed slightly better than the liver gene 
expression data in classifying the hepatotoxicants based on histopathological differences in 
liver. In a follow-up study, Huang et al. (2010) demonstrated that the transcriptomics 
markers of blood derived from the Lobenhofer et al. (2008) study were able to accurately 
predict APAP-induced liver toxicity in rats (accuracy as high as 92.1%).
The potential application of blood gene expression profiling to predict DILI has also been 
investigated in humans. No hepatotoxicity, as assessed by clinical or biochemical 
parameters, was seen in healthy volunteers who were treated with a 4-g bolus dose of APAP 
compared with those receiving placebo (Fannin et al., 2010). In spite of the absence of 
hepatotoxicity, as evidenced by the lack of any alteration in the established biochemical and 
clinical markers, significant down-regulation of genes involved in oxidative phosphorylation 
was noticed in the blood of the APAP-treated individuals. Down regulation of blood genes 
involved in oxidative phosphorylation noticed in the APAP-treated individuals is consistent 
with known mechanisms of APAP-induced liver toxicity, as the involvement of 
mitochondrial injury in APAP-induced hepatotoxicity has been very well established 
(Heinloth et al., 2004). The potential application of blood gene expression signatures to 
detect DILI in humans has also been demonstrated by Bushel et al. (2007). The human 
orthologs of the rat blood discriminatory genes for APAP-induced liver toxicity identified 
by these authors were able to distinguish APAP-intoxicated patients from control 
individuals. The cross-species application of blood gene expression markers for toxicity 
reported by Bushel et al. (2007) is significant and very encouraging in that animal models 
may be employed, at least, to develop and validate blood gene expression markers that can 
eventually be tested and applied to monitor human exposure to toxic agents that are 
commonly found in the environment and workplace.
Blood gene expression profiling and pulmonary toxicity
The application of blood gene expression profiling in detecting and studying pulmonary 
toxicity is best illustrated in the case of crystalline silica-induced pulmonary toxicity. 
Occupational exposure to crystalline silica is a major health hazard affecting millions of 
workers in the US and elsewhere (Sanderson, 1986). Virtually any activity that involves the 
movement of earth (e.g. mining, farming, construction, etc.) is considered a potential source 
for occupational exposure to crystalline silica. However, the major occupations where 
significant human exposure to crystalline silica takes place are sandblasting, silica milling, 
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surface mining and tunneling. In many cases, occupational exposure to crystalline silica 
takes place at levels much higher than the National Institute for Occupational Safety and 
Health (NIOSH) recommended exposure level (REL) of 0.05 mg m−3 (Linch et al., 1998).
The adverse health effects resulting from occupational exposure to crystalline silica have 
been recognized and identified for a long time. These include, but are not limited to, the 
development of autoimmune diseases, rheumatoid arthritis, chronic renal diseases, lupus and 
cancer (IARC, 1997; Parks et al., 1999; Steenland et al., 2001). Silicosis, however, is the 
adverse health effect that has received the most attention among those exposed 
occupationally to crystalline silica. Silicosis is an irreversible, but preventable interstitial 
lung disease, characterized by alveolar proteinosis and diffuse fibrosis resulting in 
progressively restrictive lung function and death (Castranova & Vallyathan, 2000).
Currently, chest X-ray and pulmonary function tests are routinely employed to detect 
silicosis. Both chest X-ray and pulmonary function tests rely on structural and/or functional 
impairment of the lungs associated with the development of silicosis and, therefore, are not 
capable of predicting or detecting the disease at an early, preventable stage. Therefore, 
NIOSH has recommended developing highly sensitive and non-invasive or minimally 
invasive techniques that are capable of predicting or detecting silicosis prior to the onset of 
clinical symptoms that most likely represent the irreversible stage of the disease (NIOSH, 
National Insitute for Occupational Safety and Health, 2002).
In compliance with the NIOSH recommendation, a research project was undertaken in our 
laboratory investigating the potential application of blood gene expression profiling as a 
highly sensitive surrogate approach to detect and/or to predict crystalline silica exposure and 
the resulting pulmonary toxicity. The aims of our investigation, which employed a rat 
silicosis model, were to determine (i) can global gene expression changes in the blood 
reflect silica-induced pulmonary toxicity, (ii) can blood gene expression changes indicative 
of silica-induced pulmonary toxicity appear prior to the onset of classic biochemical and 
histological changes associated with silica-induced pulmonary toxicity, (iii) can 
bioinformatics analysis of the differentially expressed genes in the blood of the silica 
exposed rats provide insights into the mechanisms underlying the pulmonary toxicity 
induced by silica exposure and (iv) can exposure to a sub-toxic concentration of crystalline 
silica be detected or predicted using a blood gene expression signature. Details regarding the 
study design of the experiment can be found in our recent publications (Sellamuthu et al., 
2011a, 2011b, 2012a, 2012b). Stated briefly, approximately 3-month-old, healthy, male 
Fischer 344 rats (CDF strain) were exposed to filtered air (control) or an aerosol of 
respirable crystalline silica (15 mg m−3, 6 h per day for 5 days). After exposure, groups of 
control and silica exposed rats were sacrificed at post-exposure time intervals of 0, 1, 2, 4, 8, 
16, 32 and 44 weeks. Bronchoalveolar lavage fluid (BALF), including the cells within it, 
and blood and lungs were collected from the rats to determine the effects of pulmonary 
exposure to crystalline silica as well as to determine lung and blood global gene expression 
profiles. The major findings of our studies are summarized below:
Inhalation exposure to crystalline silica resulted in pulmonary toxicity in the 
rats—Lactate dehydrogenase (LDH) activity in the BALF and histological changes in the 
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lungs were evaluated to determine if exposure to crystalline silica resulted in pulmonary 
toxicity in the rats. In addition, because of the prominent role played by inflammation in 
silica-induced pulmonary toxicity, the BALF levels of polymorphonuclear leukocytes 
(PMN) and the pro-inflammatory cytokine, monocyte chemotactic protein 1 (MCP1), were 
determined in the rats. Our results demonstrated that, with the exception of the 2 weeks post-
silica exposure time interval, a significant elevation in BALF LDH activity was detected in 
the silica-exposed rats compared with the corresponding time-matched control rats. Beyond 
the 2-week post-exposure time interval, a steady increase in BALF LDH activity in the rats, 
suggesting a steady progression of silica-induced pulmonary toxicity, was noticed. The 
BALF levels of PMN and MCP1 were significantly elevated and exhibited the same trend as 
that of the BALF LDH activity in the rats.
Corraboration of the progression of pulmonary toxicity during the post-silica exposure time 
intervals was supported by the lung histological changes in the rats. An acute inflammatory 
response, as evidenced from the accumulation of PMNs around small- and medium-sized 
airways, was noticed in the silica-exposed rats at the 0-week post-exposure time interval 
(Sellamuthu et al., 2011a). A further progression in histological changes in the lungs was 
noticed during the late post-exposure time intervals of 8- and 16-weeks (Sellamuthu et al., 
2011a), 32-weeks (Sellamuthu et al., 2012a) and 44-weeks (Sellamuthu et al., 2013). The 
most prominent histological changes noticed in the lungs of the silica-exposed rats at the late 
post-exposure time intervals (32- and 44-weeks) included type II pneumocyte hyperplasia 
and positive staining with trichrome stain, indicative of fibrosis (Sellamuthu et al., 2012a, 
2013). These results, therefore, suggested that inhalation exposure to crystalline silica 
resulted in pulmonary toxicity in the rats, and our rat model was appropriate to investigate 
whether blood gene expression profiling can be employed as a surrogate approach to detect 
silica-induced pulmonary toxicity.
Global gene expression changes in the blood correlated with silica-induced 
pulmonary toxicity in rats—Global gene expression profiles in the lungs and blood 
samples of the control and silica-exposed rats were determined using the RatRef-12 V1.0 
Expression BeadChip Array (Illumina, Inc., San Diego, CA, USA) as described in detail in 
our original publications (Sellamuthu et al., 2011a, 2012a). The number of significantly 
differentially expressed genes in the lung and blood samples of the silica-exposed rats, 
compared with the time-matched control rat samples, was determined at each of the post-
silica exposure time intervals. As presented in Table 1, the number of significantly 
differentially expressed genes in the target organ, lungs and the surrogate tissue, blood, 
correlated well with markers of pulmonary toxicity (BALF LDH activity) and inflammation 
(BALF PMN count and MCP1 level). These results, in agreement with several previous 
publications (Bushel et al., 2007; Huang et al., 2010; Lobenhofer et al., 2008; Umbright et 
al., 2010), confirmed the potential value of global gene expression changes in the target 
organ as an indicator of target organ toxicity. However, the better correlation noticed 
between pulmonary toxicity markers and the number of significantly differentially expressed 
genes in the blood, compared with that of the lungs, suggested that the gene expression 
changes taking place in blood, the surrogate tissue, may be better indicators of target organ 
toxicity.
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Bioinformatics analysis of the differentially expressed genes in blood 
provided molecular insights into the mechanisms of silica-induced pulmonary 
toxicity—Studies conducted over the past several years have demonstrated the potential of 
crystalline silica exposure to result in pulmonary toxicity, especially silicosis, autoimmune 
diseases, renal diseases and cancer (IARC, 1997; Parks et al., 1999; Steenland et al., 2001). 
These previous studies have also demonstrated that many of the toxic effects associated with 
crystalline silica exposure are consequences of its ability to result in oxidative stress 
(Vallyathan et al., 1997), apoptosis (Santarelli et al., 2004), gene expression changes 
(Hubbard et al., 2002) and inflammation (Porter et al., 2002). Bioinformatics analysis of the 
differentially expressed genes in the blood and lungs of silica-exposed rats (Sellamuthu et 
al., 2012a), in addition to supporting the previously recognized toxicity and health effects of 
silica, provided insights into the molecular mechanisms underlying silica-induced 
pulmonary toxicity. Bioinformatics analysis of the significantly differentially expressed 
genes in the lungs and blood of silica-exposed rats showed remarkable similarity in the 
biological functions, molecular networks and canonical pathways that were significantly 
enriched in response to silica exposure and the resulting pulmonary toxicity (Sellamuthu et 
al., 2012a). The top 10 Ingenuity Pathway Analysis (IPA) biological functions that were 
significantly enriched in the target organ, lungs, were also significantly enriched in the 
surrogate tissue, blood, of the silica-exposed rats (Fig. 1). Most of the IPA biological 
function categories that were significantly enriched in the blood of the silica-exposed rats, 
namely respiratory diseases, cell-to-cell signaling and interaction, immune cell trafficking, 
cellular movement, cancer, inflammatory response, were functions that are known to be 
associated with toxicity and health effects of silica exposure. A comparable similarity was 
noticed with respect to the canonical pathways and molecular networks that were 
significantly enriched in the lungs and the blood in response to the silica-induced pulmonary 
toxicity (Sellamuthu et al., 2012a). It has been well established that induction of 
inflammation plays a central role in the pulmonary effects of crystalline silica exposure in 
animal models (Castranova, 2004). In fact, the majority of biological functions, molecular 
networks and canonical pathways that were significantly enriched in the blood of the rats in 
response to silica-induced pulmonary toxicity were those involved in an inflammatory 
response (Sellamuthu et al., 2011a, 2011b). Given these results, blood gene expression 
profiling and bioinformatics analysis of the differentially expressed genes in the blood 
appears to be a toxicologically relevant surrogate approach to gain insights into the 
mechanisms of target organ toxicity.
Blood gene expression signature predicted exposure to a non-toxic 
concentration of silica in rats—In a separate set of experiments, a blood gene 
expression signature was tested for its ability to predict exposure of rats to silica and the 
resulting pulmonary toxicity. Blood gene expression data obtained from control rats and 
those exposed to crystalline silica at 15 mg m−3, 6 h per day for 5 days (0-week post-
exposure time interval) were used as the training set data to develop a gene expression 
signature for silica exposure and/or toxicity. A blood gene expression signature consisting of 
7 genes was identified and tested in a set of rats which were exposed to lower concentrations 
of silica (1 or 2 mg m−3, 6 h per day, 5 days). Rats exposed to silica at 2 mg m−3, 6 per day 
for 5 days resulted in mild pulmonary toxicity as evidenced from the observation of a slight, 
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but statistically significant, elevation in BALF parameters of pulmonary toxicity (LDH 
activity, albumin and protein content). In contrast, rats exposed to silica at 1 mg m−3, 6 h per 
day for 5 days did not result in any detectable pulmonary toxicity as evidenced from normal 
LDH activity and protein and albumin contents in their BALF. The predictive blood gene 
expression signature developed for silica exposure and toxicity correctly identified 7 out of 8 
rats (87.5%) that were exposed to silica at 2 mg m−3, 6 h per day for 5 days and resulted in 
mild pulmonary toxicity. Six out of eight rats (75%) that were exposed to crystalline silica at 
1 mg m−3, 6 h per day for 5 days and did not result in any detectable pulmonary toxicity 
were correctly identified as silica-exposed rats by the predictive blood gene expression 
signature. These results, therefore, demonstrated the superior sensitivity of the blood gene 
expression signature to detect/predict silica exposure and the resulting pulmonary toxicity in 
the rats. The ability of the predictive blood gene expression signature to detect silica 
exposure in the absence of pulmonary toxicity detectable by traditional approaches 
(biochemical and histological toxicity markers) in the rat model may be of significant value 
with respect to monitoring workers for occupational exposure to crystalline silica and 
potential health effects. This view is further supported by the earlier report by Bushel et al. 
(2007) that a blood gene expression signature for hepatotoxicity developed in a rat model 
was applicable in correctly identifying APAP-induced hepatotoxicity in humans.
Although the vast majority of research with respect to the application of blood gene 
expression profiling in target organ toxicity has focused on hepatotoxicity and pulmonary 
toxicity, a few studies have been reported in which blood gene expression profiling was 
employed to detect toxicity in organs other than liver and lungs.
A blood gene expression signature consisting of eight genes was identified in rats 
administered a toxic dose of the organophosphorus insecticide, methyl parathion (Umbright 
et al., 2010). The neurotoxicity signature genes identified in the methyl parathion-
administered rats were also significantly differentially expressed in rats administered 
additional neurotoxic chemicals, ethyl parathion and malathion. None of the blood genes 
comprising the neurotoxicity signature were significantly differentially expressed in the rats 
administered any one of the four hepatotoxic chemicals (acetaminophen, carbon 
tetrachloride, thioacetamide and dimethylnitrobenzene). These findings, therefore, suggest 
the ability of blood gene expression signatures to distinguish target organ toxicity.
In a study reported by Dadarkar et al. (2010a) the application of blood gene expression 
markers to detect nephrotoxicity in rats has been described. Rats were administered any one 
of four predominantly nephrotoxic drugs (cyclophosphamide, amphotericin B, gentamicin 
and cisplatin). The authors, based on their findings, suggested that changes in expression of 
the secreted phosphoprtoein 1 (SPP1) gene in whole blood cells could possibly be used as a 
surrogate marker for drug-induced nephrotoxicity.
Rocket et al. (2002) applied blood gene expression profiling to detect endocrine system 
perturbation. Overectomized rats were treated with either 17-β-estradiol or vehicle for 3 
days, and gene expression profiles were determined by microarray using RNA samples 
isolated from PBMCs and the uterus of the rats. Of the 1185 genes represented on the 
Joseph et al. Page 11













microarray, 18 were found differentially expressed in both the PBMCs and the uterus of the 
rats in response to administration of 17-β-estradiol.
Blood transcriptomics in toxicology: challenges
Like any other new development in toxicology research, the potential application of blood 
transcriptomics as a relevant surrogate approach to study target organ toxicity faces many 
challenges. Questions to consider are: Can blood gene expression profiling be employed to 
monitor human exposure to toxic agents and the resulting toxicity such as those taking place 
in the environment and workplace? How sensitive are blood gene expression changes as 
surrogate markers of target organ toxicity compared with the traditional toxicity markers? 
Can gene expression changes be detected in the blood prior to the onset of clinical 
symptoms, which most probably, represent irreversible toxicity and disease in the target 
organ? In other words, can blood gene expression changes representing target organ toxicity 
be predicted early enough to provide a window of opportunity for intervention to prevent the 
onset of serious health effects? Typically, human exposure to toxic agents, either in the 
environment or the workplace, take place at very low concentrations and may not be 
associated with the onset of immediate target organ toxicity. In addition, co-exposure to 
multiple toxic agents is likely under conditions of occupational and, especially, 
environmental exposures. Furthermore, confounding factors such as diseases, cigarette 
smoking and other life-style factors are likely to affect peripheral blood gene expression 
profiles in humans. Therefore, can blood gene expression signatures be employed as 
sensitive and specific biomarkers to detect target organ toxicity in humans?
An unequivocal observation throughout the studies conducted so far in the area of blood 
transcriptomics in toxicology is the finding of superior sensitivity of blood gene expression 
changes compared with the histological, biochemical and hematological changes as 
indicators of target organ toxicity. In a study conducted in our laboratory (Umbright et al., 
2010), rats were administered a hepatotoxic dose of APAP. Transaminase activity and 
expression levels of hepatotoxicity marker genes were determined in the blood at post-
exposure time intervals ranging from 4 h to 1 week. As presented in Fig. 2, significant 
differential expression of the hepatotoxicity marker genes in the blood was detectable as 
early as 4 h following administration of APAP. On the other hand, the earliest post-exposure 
time interval when significant elevations in transaminase activities appeared in the blood, 
suggesting the onset of hepatotoxicity, was 24 h. As described above, superior sensitivity of 
blood gene expression signatures, compared with histological, biochemical and 
hematological changes, as biomarkers for APAP-induced hepatotoxicity have been 
demonstrated by several investigators in rats (Bushel et al., 2007; Huang et al., 2008, 2010; 
Lobenhofer et al., 2008; Zhang et al., 2012). The superior sensitivity of blood gene 
expression changes indicative of hepatotoxicity induced by APAP, compared with clinical 
and biochemical markers of hepatotoxicity, have also been demonstrated in humans (Fannin 
et al., 2010). In a recent study published by Kim et al. (2011), blood gene expression 
signatures for hepatotoxicity induced by volatile organic compounds (VOCs) were 
developed in rats, and their sensitivity was compared with the traditional toxicity markers. In 
agreement with previous studies (Bushel et al., 2007; Huang et al., 2008; Lobenhofer et al., 
2008; Umbright et al., 2010; Zhang et al., 2012), the blood gene expression markers 
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identified by Kim et al. (2011) outperformed the traditional toxicity markers with respect to 
their sensitivity to detect hepatotoxicity in rats. Similar to hepatotoxicity, superior sensitivity 
of blood gene expression signatures, compared with well-established traditional toxicity 
markers, has also been demonstrated in the case of pulmonary toxicity (Sellamuthu et al., 
2011a) and neurotoxicity (Umbright et al., 2010).
Similar to sensitivity, the issue of specificity is very important in the case of blood gene 
expression signatures as surrogate markers of target organ toxicity. Is it possible to 
distinguish the toxic agent and the target organ involved in the toxicity based on blood gene 
expression marker(s)? Unfortunately, not many studies have been conducted to date directly 
investigating whether the blood gene expression markers are specific to either the toxic 
agent or the target organ involved. In our previous study (Umbright et al., 2010), rats were 
administered either APAP or methyl parathion to induce hepatotoxicity and neurotoxicity, 
respectively. Microarray analysis of total RNA isolated from blood samples of the rats 
resulted in the identification of a panel of hepatotoxicity and neurotoxicity marker genes. 
The capability of the marker genes to detect and distinguish hepatotoxicity and neurotoxicity 
was tested in rats administered additional hepatotoxic (thioacetamide, dimethylnitrobenzene, 
and carbon tetrachloride) or neurotoxic (ethyl parathion and malathion) chemicals. The 
hepatotoxicity marker genes, identified using APAP as the model compound, were found 
differentially expressed in the blood samples derived from rats that were administered the 
additional hepatotoxic chemicals and not in the blood samples of any of the rats 
administered the neurotoxic chemicals. Therefore, in spite of the limited number of 
chemicals tested in the study, our results suggested that the blood gene expression markers 
may be specific to the type of target organ toxicity involved. Dadarkar et al. (2010b) 
performed gene expression analysis and hierarchical clustering in RNA samples obtained 
from human PBMCs treated with either hepatotoxic (acetaminophen, rosiglitazone, 
fluconazole and isoniazid) or nephrotoxic (cyclophosphamide, amphotericin B, gentamicin 
and cisplatin) drugs and identified a set of 365 genes that could discriminate the two classes 
of drugs. Further support to the specificity of blood gene expression markers to target organ 
toxicity is provided by Kim et al. (2011) who investigated blood gene expression profiles in 
rats administered each of three different VOCs (dichloromethane, ethylbenzene and 
trichloroethylene). Supervised analysis identified 1217 outlier genes as a distinct molecular 
signature distinguishing VOC exposure from controls while unsupervised gene expression 
analysis resulted in a characteristic molecular signature for each VOC.
Although experimental evidence is lacking, a critical review of the literature suggests that 
the blood gene expression signature identified in our laboratory may be specific to silica-
induced pulmonary toxicity (Sellamuthu et al., 2011a). The blood gene expression signature 
identified for the silica-induced pulmonary toxicity is quite different from that reported by 
Bushel et al. (2007) for hepatotoxicity in spite of the predominance of inflammatory 
response genes in both the signatures. In spite of the central role played by inflammation in 
silica-induced pulmonary toxicity (Castranova, 2004) and the pulmonary effects associated 
with cigarette smoking (Bhalla et al., 2009), the effects of these two pulmonary toxic agents 
on blood transcriptome appear to be different. It is worth mentioning that none of the genes 
we identified as part of the blood gene expression signature for silica-induced pulmonary 
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toxicity were present among the 342 genes that were reported to be differentially expressed 
in the blood of current cigarette smokers (Charlesworth et al., 2010). Similarly, none of the 
genes identified as part of the blood gene expression signature for silica-induced pulmonary 
toxicity were found differentially expressed in the blood under conditions of inflammation 
induced by exposure to endotoxin (Calvano et al., 2005) or diesel exhaust particles (Peretz 
et al., 2007), further suggesting that the blood gene expression signature identified in our 
laboratory may be specific to silica exposure and the resulting pulmonary toxicity. However, 
additional experimental evidence is required to make a definite conclusion regarding the 
very important issue concerning specificity of blood gene expression markers either for the 
toxic agent or the target organ toxicity.
Blood gene expression profiling to monitor human exposure to toxic agents and potential 
adverse health effects
The ultimate objective of any research focused on blood gene expression profiling in 
toxicology is to prevent adverse health effects resulting from human exposure to toxic 
agents present in the environment and workplace. This will require, as described above, 
early detection of exposure to toxic agents and a clear understanding of the molecular 
mechanism(s) underlying the toxic effects. The results of studies conducted so far, mostly by 
employing animal models, have been encouraging and have demonstrated blood gene 
expression changes as sensitive indicators of early toxicity (Bushel et al., 2007; Sellamuthu 
et al., 2011a; Umbright et al., 2010).
The very same superior sensitivity of the blood transcriptome to respond to exposure to 
toxic agents may limit its potential application in monitoring human exposure to toxic 
agents. It has been fairly well recognized that the blood transcriptome is highly dynamic in 
nature and may be influenced by a plethora of endogenous and exogenous factors. Some 
factors cannot be controlled. For example, circadian rhythm is known to affect gene 
expression profiles in tissues (Almon et al., 2008; Sukumaran et al., 2010) and probably in 
the blood. In addition, various life style factors, for example, cigarette smoking 
(Charlesworth et al., 2010) and various disease conditions (Baechler et al., 2003; Borovecki 
et al., 2005; Hershey et al., 2004; Moore et al., 2005; Tang et al., 2005) may affect the 
human blood transcriptome. Obviously, the question arises whether such a dynamic system 
is suitable to monitor human exposure to toxic agents that may be present in very small 
quantities in the environment and the workplace.
It is, therefore, apparent that more research is needed in order to determine the suitability of 
blood gene expression profiling as a surrogate approach to monitor human exposure to toxic 
agents and the resulting toxicity. However, it is encouraging to notice that mechanistically 
relevant gene expression changes were detectable in the peripheral blood of individuals who 
had received a bolus of APAP that did not result in biochemical and clinical changes 
indicative of liver toxicity (Fannin et al., 2010). Similarly, the cross-species application of 
the rat blood gene expression signature for APAP-induced hepatotoxicity in human (Bushel 
et al., 2007) is also encouraging. Blood gene expression signatures can be developed and 
characterized for sensitivity and specificity using animal models and may be subsequently 
tested for their suitability to monitor human exposure to toxic agents and the resulting 
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adverse health effects. Blood gene expression profiling may, therefore, turn out to be a 
valuable, practical first step to prevent morbidity and mortality associated with exposure to 
toxic agents present in the environment and the workplace.
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Enrichment of Ingenuity Pathway Analysis (IPA) biological functions in the lungs and blood 
of silica-exposed rats. Bioinformatics analysis of the significantly differentially expressed 
genes identified in the silica-exposed rat lungs and blood was done using IPA software. The 
top 10 significantly enriched biological functions of the silica-exposed rat lungs compared 
with the control rat lungs and the same biological functions in the blood samples are 
presented to demonstrate the similarity in gene expression profile between lungs and blood 
of the silica exposed rats. Data represents the mean of six rats per group (reproduced with 
permission from Inhalation Toxicology 2012; 24: 570–579). SDEGs, significantly 
differentially expressed genes.
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Gene expression profiling is more sensitive than the traditional toxicity endpoints. A single 
acute toxic dose of acetaminophen was administered to rats. At various time intervals 
ranging from 4 h to 1 week after administration of the chemical, blood was analyzed for 
toxicity based on the activities of aspartate transaminase (AST) and alanine transaminase 
(ALT) (A) and expression of marker genes for hepatotoxicity (B). Significant alterations in 
the expression of the selected hepatotoxicity marker genes were observed in the blood 
before any significant change in the activities of transaminases suggesting the superior 
sensitivity of gene expression changes as indicators of target organ toxicity (reproduced with 
permission from Molecular and Cellular Biochemistry 2010; 335: 223–234. *p<0.05 
compared with time matched controls.
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Table 1
Correlation coefficients (r2 values) for the relationship between silica-induced pulmonary toxicity (BALF 
LDH, PMN and MCP-1) and the number of significantly differentially expressed genes (SDEGs) in the lungs 
and blood of silica-exposed rats
BALF LDH BALF PMN BALF MCP-1
Lung SDEGs 0.776 0.879 0.927
Blood SDEGs 0.831 0.923 0.958
The toxicity measurements and the number of differentially expressed genes in the silica-exposed rats at post-exposure time intervals of 0, 1, 2, 4, 
8, 16 and 32 weeks after a 1-week exposure were used to determine the correlation coefficients (r2 values) (reproduced with permission from 
Inhalation Toxicology 2012: 24: 570–579).
J Appl Toxicol. Author manuscript; available in PMC 2015 August 26.
